Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have an advanced solid tumour that has been confirmed by a tissue or cell sample, cannot be removed by surgery or has spread to other parts of the body, and can be measured using standard imaging methods
- People with colorectal cancer (bowel cancer) that is advanced, has spread, or has come back, with a specific cancer cell type called adenocarcinoma, and whose cancer has continued to grow after receiving standard chemotherapy treatments such as 5-FU, irinotecan, and/or oxaliplatin (where those treatments were available and suitable)
- People with a specific type of lung cancer (NSCLC) that is at an advanced stage (Stage IIIB, Stage IV, or has returned), who have already received and then experienced disease progression on a type of immunotherapy called anti-PD-(L)1 therapy (where available)
- People with advanced or metastatic stomach cancer (gastric cancer) who have already received at least one standard treatment and either could not tolerate it or whose cancer continued to grow on it, or whose cancer came back within 6 months of completing additional treatment after surgery
- People with stomach cancer who have a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity but able to carry out light work) (confirm with trial site)
Who may not be able to join:
- People who have previously had a severe allergic reaction (anaphylaxis) to irinotecan or bevacizumab
- People who have previously received a treatment specifically targeting a protein called CEACAM5
- People who have had a serious (Grade 3 or higher) lung inflammation condition known as interstitial lung disease or pneumonitis
- People who do not meet other additional requirements set out in the trial protocol (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+61756132480
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participnats with Adverse Events (AEs); Number of participants with Serious AEs (SAEs); Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of deaths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.